“Unexpected” CDH1 Variants Lead to Uncertainty, Experts Warn
Unexpectedly identifying a patient as a CDH1 carrier can lead to a “difficult conundrum” for clinicians and patients, highlighting the need for pretest counseling.
Gastric Cancer
Small Intestinal GISTs May Have Worse Clinical Features and Outcomes
Compared with patients who had gastric gastrointestinal stromal tumors (GISTs), patients with small intestinal GISTs had worse survival and clinical features.
T2DM Increases Gastric Cancer Risk After H. Pylori Eradication
Targeted screening should be considered in high-risk patients following H. pylori eradication therapy.
Biosimilar Kanjinti Gets FDA Approval for Breast, Gastric Cancer
Kanjinti, a HER2/neu receptor antagonist, is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative.
Pembrolizumab Found as Effective as Chemotherapy for Gastric Cancers
Initial therapy with pembrolizumab may result in comparable overall survival as standard chemotherapy in patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.
Docetaxel Plus S-1 Postoperative Chemotherapy in Stage III Gastric Cancer Found to Improve RFS
Based on an interim analysis showing efficacy for postoperative docetaxel plus S-1 compared with S-1 alone, this trial in stage III gastric cancer was closed early.
Distinct Clinical and Molecular Features Linked to Early-Onset Colorectal Cancer
Some patients with colorectal cancer are more likely to have disease characterized by a high frequency of mutations, microsatellite instability, and strong immune activation.
Differences in the Diagnosis, Management, and Outcomes of Hispanic Patients With Gastric Cancer Revealed
A retrospective study of patients with gastric cancer in the United States showed differences in patient- and disease-related characteristics, as well as different frequencies of staging laparoscopy, treatment/surgical approaches, and specific clinical outcomes, for those of Hispanic compared with non-Hispanic ethnicity. This study was published in the Journal of Surgical Oncology. In the US, the incidence of gastric…
Lonsurf Gains Metastatic Gastric Cancer Indication
The Food and Drug Administration has approved Lonsurf (trifluridine and tipiracil; Taiho Oncology) for the treatment of adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. The approval was based…
MET Inhibitor as a Monotherapy in GI Cancers: Unlikely Beneficial
The study was halted when patient response rates were lower than those seen across a similar trial involving the drug.
Next post in Gastrointestinal Cancers
